Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management

Zab Mosenifar, MD


March 06, 2023

Current clinical practice guidelines recommend the antifibrotic agent nintedanib for patients with PPF who have failed standard management for fibrotic ILD. The INBUILD clinical trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients with chronic fibrosing ILD. In addition, nintedanib may still be effective when used in combination with immunomodulatory therapies.

Learn more about medication for PF-ILD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.